{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:58:34Z","timestamp":1781823514270,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004091","name":"Kumamoto University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jconrel.2020.05.036","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T21:40:08Z","timestamp":1590183608000},"page":"522-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects"],"prefix":"10.1016","volume":"324","author":[{"given":"Hiroshi","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Miyahisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4240-2473","authenticated-orcid":false,"given":"Mayuko","family":"Chikamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Minayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Ichimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kobashigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.05.036_bb0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0015","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmet.2013.12.017","article-title":"Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans","volume":"19","author":"Lee","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1101\/gad.177857.111","article-title":"FGF21 regulates PGC-1\u03b1 and browning of white adipose tissues in adaptive thermogenesis","volume":"26","author":"Fisher","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cmet.2010.02.001","article-title":"Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat","volume":"11","author":"Hondares","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0035","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0040","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1210\/en.2011-0281","article-title":"Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo","volume":"152","author":"Fisher","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0045","article-title":"Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tem.2014.03.001","article-title":"FGF21-based pharmacotherapy--potential utility for metabolic disorders","volume":"25","author":"Gimeno","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0055","doi-asserted-by":"crossref","first-page":"E1105","DOI":"10.1152\/ajpendo.00348.2009","article-title":"Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects","volume":"297","author":"Xu","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0065","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0070","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/BJ20151085","article-title":"Circulating FGF21 proteolytic processing mediated by fibroblast activation protein","volume":"473","author":"Zhen","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0075","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.drudis.2013.10.021","article-title":"Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome","volume":"19","author":"Zhang","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0080","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00065","article-title":"The starvation hormone, fibroblast growth factor-21, extends lifespan in mice","volume":"1","author":"Zhang","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0090","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1015396825274","article-title":"Pharmaceutical strategies utilizing recombinant human serum albumin","volume":"19","author":"Chuang","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0095","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1358\/dot.2007.43.8.1067343","article-title":"Recombinant human serum albumin","volume":"43","author":"Chuang","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0100","first-page":"682","article-title":"Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics","volume":"5","author":"Sand","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0105","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.2337\/diabetes.53.9.2492","article-title":"A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0110","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","article-title":"Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients","volume":"120","author":"Santagostino","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2010.05.020","article-title":"Albumin fusion of thioredoxin--the production and evaluation of its biological activity for potential therapeutic applications","volume":"147","author":"Ikuta","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2011.05.013","article-title":"Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury","volume":"154","author":"Furukawa","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0125","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ki.2012.429","article-title":"A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy","volume":"83","author":"Kodama","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0130","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbagen.2013.12.007","article-title":"Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity","volume":"1840","author":"Kodama","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1124\/jpet.112.201814","article-title":"Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression","volume":"345","author":"Tanaka","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0140","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1021\/mp400690v","article-title":"Albumin fusion prolongs the antioxidant and anti-inflammatory activities of thioredoxin in mice with acetaminophen-induced hepatitis","volume":"11","author":"Tanaka","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0145","doi-asserted-by":"crossref","first-page":"14471","DOI":"10.1038\/srep14471","article-title":"Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury","volume":"5","author":"Nishida","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0150","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00125-017-4322-3","article-title":"The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes","volume":"60","author":"Bus","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/dom.12408","article-title":"Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function","volume":"17","author":"Kim","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058575","article-title":"Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319","volume":"8","author":"Kharitonenkov","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0165","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1210\/en.2012-1211","article-title":"Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys","volume":"153","author":"V\u00e9niant","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0175","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A novel fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-klotho, and enhanced efficacy in mice and Cynomolgus monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0180","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11095-006-9933-1","article-title":"Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin","volume":"23","author":"Matsushita","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0185","first-page":"1","article-title":"The effect of homocysteine on the expression of CD36, PPAR\u03b3, and C\/EBP\u03b1 in adipose tissue of normal and obese mice","author":"Mentese","year":"2019","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.jconrel.2020.05.036_bb0190","doi-asserted-by":"crossref","first-page":"106404","DOI":"10.1016\/j.prostaglandins.2019.106404","article-title":"Cd36 gene expression in adipose and hepatic tissue mediates the lipids accumulation in liver of obese rats with sucrose-induced hepatic steatosis","volume":"147","author":"Quintana-Castro","year":"2019","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2018.03.015","article-title":"Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action","volume":"277","author":"Gilroy","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.036_bb0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-12-56","article-title":"Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma","volume":"12","author":"Miura","year":"2012","journal-title":"BMC Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592030314X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592030314X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:53:35Z","timestamp":1759161215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592030314X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":40,"alternative-id":["S016836592030314X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}